Literature DB >> 32550986

PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2020        PMID： 32550986      PMCID： PMC7294551          DOI： 10.1021/acsmedchemlett.0c00236

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  A magic drug target: Androgen receptor.

Authors:  Dan Li; Wenfang Zhou; Jinping Pang; Qin Tang; Bingling Zhong; Chao Shen; Li Xiao; Tingjun Hou
Journal:  Med Res Rev       Date:  2018-12-19       Impact factor: 12.944

Review 2.  Targeting Nuclear Receptors with PROTAC degraders.

Authors:  John J Flanagan; Taavi K Neklesa
Journal:  Mol Cell Endocrinol       Date:  2019-05-21       Impact factor: 4.102

Review 3.  Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer.

Authors:  Wen-Jing Liu; Gang Zhao; Chen-Yan Zhang; Chang-Qing Yang; Xiang-Bin Zeng; Jin Li; Kun Zhu; Shi-Qi Zhao; Hui-Meng Lu; Da-Chuan Yin; Sheng-Xiang Lin
Journal:  J Cell Biochem       Date:  2019-11-06       Impact factor: 4.429

Review 4.  DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer.

Authors:  Vincent Giguère
Journal:  Trends Cancer       Date:  2020-02-18
  4 in total
  1 in total

Review 1.  Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening.

Authors:  Federica Pedrucci; Claudia Pappalardo; Giovanni Marzaro; Nicola Ferri; Alberto Ferlin; Luca De Toni
Journal:  Int J Mol Sci       Date:  2022-06-14       Impact factor: 6.208
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.